Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes

被引:27
|
作者
Boehm, Anna-Katharina [1 ]
Schneider, Udo [2 ]
Aberle, Jens [3 ]
Stargardt, Tom [1 ]
机构
[1] Univ Hamburg, Hamburg Ctr Hlth Econ, Hamburg, Germany
[2] Techniker Krankenkasse, Hamburg, Germany
[3] Univ Hosp Hamburg Eppendorf, Univ Obes Ctr Hamburg, Dept Endocrinol & Diabetol, Hamburg, Germany
来源
PLOS ONE | 2021年 / 16卷 / 05期
关键词
DUAL THERAPY; MONOTHERAPY; NONADHERENCE; PERSISTENCE; COPAYMENTS; IMPACT;
D O I
10.1371/journal.pone.0250993
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Suboptimal patient adherence to pharmacological therapy of type 2 diabetes may be due in part to pill burden. One way to reduce pill burden in patients who need multiple medications is to use fixed-dose combinations. Our study aimed to compare the effects of fixed-dose combination versus loose-dose combination therapy on medication adherence and persistence, health care utilization, therapeutic safety, morbidities, and treatment modification in patients with type 2 diabetes over three years. Methods Using administrative data, we conducted a retrospective controlled cohort study comparing type 2 diabetes patients who switched from monotherapy to either a fixed-dose combination or a loose-dose combination. Adherence was assessed as the primary endpoint and calculated as the proportion of days covered with medication. After using entropy balancing to eliminate differences in observable baseline characteristics between the two groups, we applied difference-in-difference estimators for each outcome to account for time-invariant unobservable heterogeneity. Results Of the 990 type 2 diabetes patients included in our analysis, 756 were taking a fixed-dose combination and 234 were taking a loose-dose combination. We observed a statistically significantly higher change in adherence (year one: 0.22, p<0.001, year two: 0.25, p<0.001, and year three: 0.29, p<0.001) as well as higher persistence and a smaller change in the number of drug prescriptions in each of the three years in the fixed-dose combination group compared to the loose-dose combination group. The differences were most pronounced in patients who were poorly adherent, had a high pill burden, or did not have a severe concomitant disease. Conclusion Our results indicate that taking a fixed-dose combination can lead to a significant improvement in adherence to pharmacological therapy of type 2 diabetes compared to a loose-dose combination. In particular, these findings suggest that reducing pill burden may improve disease management among patients with more complex medication demand and patients who have demonstrated poor medication adherence.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients
    Boehm, Anna-Katharina
    Schneider, Udo
    Stargardt, Tom
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2023, 21 (01) : 109 - 118
  • [2] Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients
    Anna-Katharina Böhm
    Udo Schneider
    Tom Stargardt
    [J]. Applied Health Economics and Health Policy, 2023, 21 : 109 - 118
  • [3] Understanding Predictors of Compliance in Fixed-Dose Combination vs Loose-Dose Combination Therapy for Treatment of Type 2 Diabetes
    Gwadry-Sridhar, Femida
    Leslie, R. Scott
    Patel, B.
    Sanchez-Trask, Lisa
    [J]. DIABETES, 2010, 59 : A346 - A346
  • [4] Medication persistence and adherence in type 2 diabetes patients using fixed- versus loose-dose combination products
    Sorstadius, E.
    Lokhandwala, T.
    Lee, W.
    Smith, N.
    Sternhufvud, C.
    Mukherjee, J.
    [J]. DIABETOLOGIA, 2015, 58 : S179 - S180
  • [5] Adherence to Oral Antidiabetic Agents with Pioglitazone and Metformin: Comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy
    Barner, Jamie C.
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (09) : 1281 - 1288
  • [6] Clinical and economic outcomes in type 2 diabetes patients treated with fixed-dose versus loose-dose combination anti-hyperglycaemic therapies
    Vlahiotis, A.
    Wittbrodt, E.
    Patel, J.
    Bell, K. F.
    Riehle, E.
    [J]. DIABETOLOGIA, 2017, 60 : S423 - S423
  • [7] A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs
    Lokhandwala, Tasneem
    Smith, Nancy
    Sternhufvud, Catarina
    Sorstadius, Elisabeth
    Lee, Won Chan
    Mukherjee, Jayanti
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 203 - 212
  • [8] FIXED-DOSE COMBINATION THERAPY IN TYPE 2 DIABETES MELLITUS
    Blonde, Lawrence
    Juan, Zinnia T. San
    Bolton, Peggy
    [J]. ENDOCRINE PRACTICE, 2014, 20 (12) : 1322 - 1332
  • [9] Fixed-dose combination therapy for hypertension in diabetes
    不详
    [J]. DIABETES OBESITY & METABOLISM, 1999, 1 (06): : 361 - 362
  • [10] Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone
    Bailey, Clifford J.
    Green, Brian D.
    Flatt, Peter R.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (08) : 1017 - 1025